3 hours ago
1
J Studios/DigitalVision via Getty Images
- RAPT Therapeutics (NASDAQ:RAPT) is up ~32% in Monday trading after reporting topline phase 2 data on chronic spontaneous urticaria candidate RPT904.
- The trial, which is being conducted in China, is comparing RPT904 against Roche (OTCQX:RHHBY) and Novartis' (
English (US) ·